Impact of HLA-G +3142C>G on the development of antibodies to blood group systems other than the Rh and Kell among sensitized patients with sickle cell disease.

Autor: Martins JO; Serviço de Hemoterapia da UNIFESP, São Paulo, Brazil. Electronic address: caludinardo@gmail.com., Pagani F; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil. Electronic address: flavia.pagani@prosangue.sp.org.br., Dezan MR; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil., Oliveira VB; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil., Conrado M; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil., Ziza KC; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil., Gualandro SFM; Hematology Unit, University of São Paulo, School of Medicine, Brazil., Langui DM; Serviço de Hemoterapia da UNIFESP, São Paulo, Brazil., Bordin JO; Serviço de Hemoterapia da UNIFESP, São Paulo, Brazil., Rocha V; Serviço de Hemoterapia da UNIFESP, São Paulo, Brazil; Hematology Unit, University of São Paulo, School of Medicine, Brazil; Department of Hematology, Churchill Hospital, NHS BT, Oxford University, Oxford, United Kingdom., Mendrone-Júnior A; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil., Dinardo CL; Serviço de Hemoterapia da UNIFESP, São Paulo, Brazil; Fundação Pró-Sangue São Paulo Hemocenter, São Paulo, Brazil; Institute of Tropical Medicine, University of São Paulo, School of Medicine, São Paulo, Brazil. Electronic address: cldinardo@prosangue.sp.gov.br.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2022 Oct; Vol. 61 (5), pp. 103447. Date of Electronic Publication: 2022 Apr 27.
DOI: 10.1016/j.transci.2022.103447
Abstrakt: Background: Patients' inflammatory history is an important factor underlying red blood cell (RBC) alloimmunization, which is a frequent transfusion complication among individuals with sickle cell disease (SCD). HLA-G has been associated with different inflammatory and auto - immune diseases. Our goal was to verify whether the HLA-G + 3142 C>G and 14-bp Ins/Del variations are associated with RBC antibody development among SCD patients.
Methods: This was a single-center case-control study. SCD patients were randomly selected for the study and divided into two groups: 'Alloimmunized' and 'Nonalloimmunized' depending on the presence of irregular antibodies. The 'Alloimmunized'group was further divided into two subgroups according to the presence of only antibodies against the Rh and Kell blood group systems or the existence of antibodies to antigens of the other blood group systems.
Results: A total of 213 patients were included in the study (110 alloimmunized and 103 non-alloimmunized). The 'Alloimmunized' and 'Non-alloimmunized' groups did not differ statistically regarding the HLA-G + 14 bp Ins/Del ( p = 0.494) and + 3142 C>G ( p = 0.334). Individuals who had only antibodies against the Rh and Kell antigens had a frequency of HLA-G + 3142GG genotype almost twice as high compared to the groupwith antibodies against less immunogenic antigens ( p = 0.043).
Conclusions: The genotype frequency of HLA-G + 3142 C>G differs among alloimmunized SCD patients, depending on the presence of antibodies against low immunogenic RBC antigens. This highlights a possible role played by the HLA-G molecule in the RBC alloimmunization process.
Competing Interests: Conflicts of interest The authors declare no conflicts of interest.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: